| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/08/2001 | CA2378879A1 Serotonergic benzothiophenes |
| 02/08/2001 | CA2378878A1 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists |
| 02/08/2001 | CA2378331A1 Calcium channel transport polynucleotides, polypeptides, and antibodies |
| 02/08/2001 | CA2378302A1 Thienopyranecarboxamide derivatives |
| 02/08/2001 | CA2376927A1 Oxazinocarbazoles for the treatment of cns diseases |
| 02/08/2001 | CA2374743A1 Human chaperone proteins |
| 02/07/2001 | EP1074634A1 Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease |
| 02/07/2001 | EP1074620A1 Monomeric protein of the TGF-beta family |
| 02/07/2001 | EP1074619A2 Promoter for neuropeptide FF and use thereof for therapy and diagnostics |
| 02/07/2001 | EP1074618A2 Cadherin materials and methods |
| 02/07/2001 | EP1074550A1 Process for the preparation of 3-substituted 4-phenyl-piperidine derivatives |
| 02/07/2001 | EP1074257A1 2,7-Substituted octahydro-1H-pyrido (1,2-A)pyrazine derivatives as ligands for serotonin receptors |
| 02/07/2001 | EP1074252A2 Composition comprising theanine for suppressing behaviour problems of pets |
| 02/07/2001 | EP1073758A1 Retroviral vectors including modified envelope escort proteins |
| 02/07/2001 | EP1073739A2 Cd40-interacting and traf-interacting proteins |
| 02/07/2001 | EP1073738A2 Human k+ ion channel and therapeutic applications thereof |
| 02/07/2001 | EP1073736A1 Delayed rectifier potassium channel subunit |
| 02/07/2001 | EP1073723A2 Ste20-related protein kinases |
| 02/07/2001 | EP1073681A1 Cloning of a novel 7tm receptor axor-2 |
| 02/07/2001 | EP1073664A1 (alpha-aminophosphino) peptidesderivative and compositions containing same |
| 02/07/2001 | EP1073658A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| 02/07/2001 | EP1073652A1 Paroxetine maleate |
| 02/07/2001 | EP1073651A1 Indolyl derivatives as serotonergic agents |
| 02/07/2001 | EP1073645A2 Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds |
| 02/07/2001 | EP1073641A2 New substituted amides, their production and their use |
| 02/07/2001 | EP1073639A1 Quinoline derivatives |
| 02/07/2001 | EP1073638A1 Heterocyclically substituted amides, their production and their use |
| 02/07/2001 | EP1073636A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists |
| 02/07/2001 | EP1073635A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors |
| 02/07/2001 | EP1073632A1 Substituted benzamides, their production and their use as cysteine protease inhibitors |
| 02/07/2001 | EP1073631A1 New substituted amides, their production and their use |
| 02/07/2001 | EP1073466A1 Solution containing nicotine |
| 02/07/2001 | EP1073455A1 Compositions and methods for extending the action of clostridial neurotoxin |
| 02/07/2001 | EP1073437A1 Treatment of generalized anxiety disorder with paroxetine |
| 02/07/2001 | EP1073432A2 Use of glycine site agonists or glycine uptake inhibitors for treating neuropsychiatric disorders |
| 02/07/2001 | EP1073334A1 Serotonin potentiation by oleamide analogs |
| 02/07/2001 | EP0922035B1 Tetrahydroisoquinoline derivatives and their pharmaceutical use |
| 02/07/2001 | EP0799226B1 Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists |
| 02/07/2001 | EP0789702B1 Substituted tetracyclic oxazepine and thiazepine derivatives with 5-ht2 receptor affinity |
| 02/07/2001 | EP0538422B1 New use of diphenylbutylpiperazinecarboxamides in the treatment of substance disorders |
| 02/07/2001 | CN1283201A K receptor opioid peptides |
| 02/07/2001 | CN1283185A New crystalline polymorphic form of 1-methyl-5-p-toluoylpyrroel-2-acetamidoacetic acid guaiacyl ester (MED 15) |
| 02/07/2001 | CN1283183A Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| 02/07/2001 | CN1283177A Process for the preparation of isopropyl-methyl-[2-(3-N-Propoxyphenoxy) ethyl] amine |
| 02/07/2001 | CN1283116A Method of reducing craving in mamals |
| 02/07/2001 | CN1283114A Benzoxazine compounds for enhancing synaptic response |
| 02/07/2001 | CN1283083A Revitalisation formulation |
| 02/07/2001 | CN1282743A New beta-carbiline compounds, their preparation method and medicine composition conterning same |
| 02/07/2001 | CN1061658C Tricyclic benzazepine vasopression antagonists |
| 02/07/2001 | CN1061654C Process for preparation of tetrazole derivatives |
| 02/07/2001 | CN1061653C Benzofuran compounds, process for their preparation and pharmaceutical compositions thereof |
| 02/07/2001 | CN1061552C Epilepsy recovering pill and preparing process thereof |
| 02/07/2001 | CN1061536C Tablet for clearing head for cerebrorascular disease |
| 02/06/2001 | US6184351 Artificial brain protein; for the treatment of alzheimer's and parkinson's disease |
| 02/06/2001 | US6184251 Use of arachidonic acid and/or docosahexanoic acid for the treatment of dyspraxia |
| 02/06/2001 | US6184248 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 02/06/2001 | US6184244 C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/06/2001 | US6184237 Substituted pyridine compounds and methods of use |
| 02/06/2001 | US6184236 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative |
| 02/06/2001 | US6184231 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 02/06/2001 | US6184229 For treatment of disorders associated with the disfunctioning of nicotinic receptors |
| 02/06/2001 | US6184227 Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
| 02/06/2001 | US6184223 Reverse-turn mimetics and methods relating thereto |
| 02/06/2001 | US6184222 Administering norepinephrine reuptake inhibitor selective for norepinephrine over other neurotransmitters; side effect reduction |
| 02/06/2001 | US6184219 Composition and methods employing it for the treatment of 5-HT-mediated disorders |
| 02/06/2001 | US6184218 Mixture of citalopram and (r)-3-n,n-dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1-benzopyran-5 -carboxamide hydrogen (2r,3r)-tartrate monohydrate (nad-299); antidepressants |
| 02/06/2001 | US6184217 Administering antiinflammatory dosage of a ring-substituted indolocarbazole derivative compound; tumor necrosis factor (tnf) inhibitors |
| 02/06/2001 | US6184200 Truncated glial cell line-derived neurotrophic factor |
| 02/06/2001 | US6184025 Nucleotide sequences for the detection and diagnosis of viral diseases |
| 02/06/2001 | US6183993 Complement-resistant non-mammalian DNA viruses and uses thereof |
| 02/06/2001 | US6183780 May be used for the application of active substances whenever a certain lag-time before release is advantageous, such as in be the case of anti-asthmatics, anti-emetics, cardiotonics, vasodilators, anti-vertigo and anti-meniere. |
| 02/06/2001 | US6183775 Buccal delivery system |
| 02/06/2001 | CA2314798A1 1,2,4,5-tetrahydro-benzo[d]azepin derivatives |
| 02/05/2001 | CA2314867A1 2,7-substituted octahydro-1h-pyrido¬1,2-a|pyrazine derivatives as ligands for serotonin receptors |
| 02/03/2001 | CA2314746A1 Use of flupirtin for amelioration of pains in the degenerative joint diseases of dogs and cats |
| 02/02/2001 | CA2314750A1 Process for the preparation of 3-substituted 4-phenyl-piperidine derivatives |
| 02/01/2001 | WO2001007658A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007477A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 02/01/2001 | WO2001007474A1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 02/01/2001 | WO2001007473A1 Peptides containing n-substituted l-amino acids for preventing beta-strand association |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007470A2 Human nervous system-associated proteins |
| 02/01/2001 | WO2001007459A1 29 human secreted proteins |
| 02/01/2001 | WO2001007453A1 Tricyclic monosaccharide derivatives useful in treating acute ischemia-induced neurodegeneration |
| 02/01/2001 | WO2001007442A1 Beta-amyloid peptide inhibitors |
| 02/01/2001 | WO2001007436A2 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | WO2001007435A2 N-(indolcarbonyl-)piperazin derivatives als 5-ht2a-receptor ligands |
| 02/01/2001 | WO2001007434A2 Indole derivatives and their use as 5ht2a ligands |
| 02/01/2001 | WO2001007424A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 02/01/2001 | WO2001007405A2 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 02/01/2001 | WO2001007067A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | WO2001007066A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | WO2001007063A1 Process for the extraction of valerian root |
| 02/01/2001 | WO2001007043A1 Azetidine carboxamide derivatives for the treatment of cns disorders |
| 02/01/2001 | WO2001007023A2 Azetidine compounds in cns and eye diseases |
| 02/01/2001 | WO2001007022A2 Azetidine compounds in cns and eye diseases |
| 02/01/2001 | WO2001006989A2 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 02/01/2001 | WO2001006987A2 Transnasal anticonvulsive compositions and modulated process |